Maxigen Biotech Inc. (MBI) was formed by a group of entrepreneurs and scientists in December 1998. With headquarters in Taipei, Taiwan, MBI has utilized its core competence in biopolymers and developed a broad range of applications in areas such as medical devices and skincare products. MBI specializes in the developing, manufacturing, and marketing of biomedical and cosmeceutical skincare products. Our major shareholders include GIH Group, Mega International Commercial Bank, First Financial Holding, and Nasdaq-listed medical device company – NuVasive Inc.
MBI has developed a rich pipeline of biomedical products which consists of FormaGraft®, Foramic®, ArtiAid®, ophthalmic viscoelastic - ViscAid®, and surgical and dental wound dressing - SurgiAid®. In accordance to the growing trend of minimally invasive surgery, MBI has also developed several biomedical applications, such as injectable bone graft and anti-adhesive. Our biomedical products have received market approval and certification for Taiwan, US and the EU market, and have been successfully launched on the US, Southeast Asia, the Middle East, and other new emerging markets.
MBI’s cosmeceutical products addresses various skin care needs, including whitening, anti-aging, and anti-wrinkle. Our skincare products and masks are distributed throughout the global market under various internationally renowned labels. Recently, by utilizing our core technology in developing collagen and hyaluronic acid, MBI has developed an assortment of skincare products under our own labels, Dr. Neo, BIOFLASH and NéoRenée for different skin types and customer needs.